CLINICAL TRIALS PROFILE FOR NAFTIFINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for naftifine hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00253305 ↗ | Topical Gel Anti-Fungal Agent for Tinea Unguium | Completed | MediQuest Therapeutics | Phase 2 | 2005-09-01 | The purpose of this study is to compare, in a controlled fashion, the response to two anti-fungal agents, naftifine or terbinafine, with vehicle in novel topical gel formulations in the treatment of subjects with distal subungual tinea unguium of the toenails (onychomycosis). The formulation used as the vehicle for the active agents has been shown in earlier studies to facilitate the penetration of the active agent through fungally-infected nails. This study will examine dose-response and agent differences in terms of efficacy and safety. Once the subject has qualified for the study, he/she will be randomly assigned to one of five study groups, dispensed appropriate study medication and instructed to apply one drop to the great toe designated for study. |
| NCT01580891 ↗ | Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis | Completed | Taro Pharmaceuticals USA | Phase 1 | 2012-05-01 | The objective of this study is to evaluate the efficacy and safety of the test formulation of Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.) as compared to the already marketed formulation Naftin® (Naftifine HCl) 1% Cream (Merz Pharmaceuticals) and placebo in patients with tinea pedis and to show the superiority of the active treatments over placebo when dosed once a day for 28 days. |
| NCT01712360 ↗ | Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis | Completed | Merz North America, Inc. | Phase 4 | 2012-10-01 | This study is being done to see how the body is affected when a study drug is applied to both feet if the subject has athlete's foot or to both feet and the groin area if the subject has both athlete's foot and jock itch. Safety of the drug and how well the drug works will also be measured. |
| NCT01712360 ↗ | Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis | Completed | Merz Pharmaceuticals, LLC | Phase 4 | 2012-10-01 | This study is being done to see how the body is affected when a study drug is applied to both feet if the subject has athlete's foot or to both feet and the groin area if the subject has both athlete's foot and jock itch. Safety of the drug and how well the drug works will also be measured. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for naftifine hydrochloride
Condition Name
Clinical Trial Locations for naftifine hydrochloride
Trials by Country
Clinical Trial Progress for naftifine hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for naftifine hydrochloride
Sponsor Name
